Drug Profile
Research programme: cancer therapeutics - Centocor/Thallion
Latest Information Update: 03 Jul 2023
Price :
$50
*
At a glance
- Originator Centocor
- Developer BELLUS Health
- Class Monoclonal antibodies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer